The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Steven Y C, Mora, Jocelyn, Bowen, Asha C, Cheng, Matthew P, Daneman, Nick, Goodman, Anna L, Heriot, George S, Lee, Todd C, Lewis, Roger J, Lye, David C, Mahar, Robert K, Marsh, Julie, McGlothlin, Anna, McQuilten, Zoe, Morpeth, Susan C, Paterson, David L, Price, David J, Roberts, Jason A, Robinson, J Owen, van Hal, Sebastiaan J, Walls, Genevieve, Webb, Steve A, Whiteway, Lyn, Yahav, Dafna, Davis, Joshua S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Viewpoints Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710697/
https://www.ncbi.nlm.nih.gov/pubmed/35717634
http://dx.doi.org/10.1093/cid/ciac476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710697/
https://www.ncbi.nlm.nih.gov/pubmed/35717634
http://dx.doi.org/10.1093/cid/ciac476

Ejemplares similares